Why the study?
Does enoxaparin reduce hospital-acquired VTE, adverse events, and costs compared to unfractionated heparin in hospitalized patients at risk of VTE?
Population
5,136 US hospitalised medical and surgical patients aged ≥40 years, at risk of VTE according to the 7th ACCP…
Comparison
Appropriate ACCP-recommended enoxaparin… vs Appropriate ACCP-recommended unfractionated…
Design
Cohort
Follow-up
In-hospital (duration of hospital stay ≥6 days)
Authors
Loading...
May support enoxaparin over UFH for VTE prophylaxis in at-risk inpatients; leaves open need for RCTs to confirm association.
Does enoxaparin reduce hospital-acquired VTE, adverse events, and costs compared to unfractionated heparin in hospitalized patients at risk of VTE?
In hospitalized patients at risk of VTE, appropriate enoxaparin prophylaxis is associated with lower rates of hospital-acquired VTE, pulmonary embolism, and adverse events compared to unfractionated heparin.
Lin et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: